Effect of Ketoconazole on the Pharmacokinetics of Refametinib
Effect of Ketoconazole on the Pharmacokinetics of Refametinib
The purpose of this study is to see if there is a difference between the way your body
 absorbs and distributes BAY86-9766 when given alone or in combination with ketoconazole, a
 drug which may affect how much BAY86-9766 is absorbed, distributed or eliminated from the
 body
Inclusion Criteria:

 -  Healthy male subject

 -  Age: 18 to 45 years (inclusive) at the first screening examination / visit

 -  Body mass index (BMI): 18.5 to 32 kg/m² (inclusive)

 -  Ability to understand and follow study-related instructions. Subject, who is a
 sexually active man and has not been surgically sterilized, must consent that he uses
 a condom during intercourse and ensures that his female partner practices adequate
 contraception, or he must be willing to refrain from sexual intercourse from the
 beginning of the trial (signing of the informed consent) until 30 days after last
 study drug administration

 Exclusion Criteria:

 -  Clinically significant disease or condition

 -  Retinal pathology or vien occlusion

 -  Left Ventricular ejection Fraction(LVEF) <60% (as measured at screening) by Multiple
 Gated Acquisition Scan(MUGA) or echocardiogram